A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19.

Autor: Zhou Y; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, US., Liu Y; Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, US., Gupta S; Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, US.; Department of Computational Biology, Cornell University, Ithaca, NY 14853, US., Paramo MI; Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, US.; Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853, US., Hou Y; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, US., Mao C; Division of Health and Biomedical Informatics, Department of Preventive Medicine, Northwestern University, Chicago, IL 60611, US., Luo Y; Division of Health and Biomedical Informatics, Department of Preventive Medicine, Northwestern University, Chicago, IL 60611, US., Judd J; Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853, US., Wierbowski S; Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, US.; Department of Computational Biology, Cornell University, Ithaca, NY 14853, US., Bertolotti M; Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, US., Nerkar M; Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853, US., Jehi L; Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, US., Drayman N; Pritzker School of Molecular Engineering, The University of Chicago, Chicago, IL 60637, US., Nicolaescu V; Department of Microbiology, Ricketts Laboratory, University of Chicago, Chicago, IL 60637, US., Gula H; Department of Microbiology, Ricketts Laboratory, University of Chicago, Chicago, IL 60637, US., Tay S; Pritzker School of Molecular Engineering, The University of Chicago, Chicago, IL 60637, US., Randall G; Department of Microbiology, Ricketts Laboratory, University of Chicago, Chicago, IL 60637, US., Lis JT; Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853, US., Feschotte C; Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853, US., Erzurum SC; Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, US., Cheng F; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, US.; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, US.; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, US., Yu H; Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, US.; Department of Computational Biology, Cornell University, Ithaca, NY 14853, US.

Publikováno v: Research square [Res Sq] 2022 Jun 07. Date of Electronic Publication: 2022 Jun 07.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A comprehensive SARS-CoV-2-human protein-protein interactome network reveals novel pathobiology and host-targeting therapies for COVID-19

Autor: Yadi Zhou, Yuan Liu, Shagun Gupta, Mauricio I. Paramo, Yuan Hou, Chengsheng Mao, Yuan Luo, Julius Judd, Shayne Wierbowski, Marta Bertolotti, Mriganka Nerkar, Lara Jehi, Nir Drayman, Vlad Nicolaescu, Haley Gula, Savaş Tay, Glenn Randall, John T. Lis, Cédric Feschotte, Serpil C. Erzurum, Feixiong Cheng, Haiyuan Yu

Physical interactions between viral and host proteins are responsible for almost all aspects of the viral life cycle and the host’s immune response. Studying viral-host protein-protein interactions is thus crucial for identifying strategies for tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e135651c97340424c112247d7014dc56
https://doi.org/10.21203/rs.3.rs-1354127/v1

Host-targeting therapies for hepatitis C virus infection: current developments and future applications

Autor: Florian Wrensch, Thomas F. Baumert, Catherine Schuster, Mirjam B. Zeisel, Emilie Crouchet

Publikováno v: Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology, Sage Publishing, 2018, 11, ⟨10.1177/1756284818759483⟩
Therapeutic Advances in Gastroenterology, Vol 11 (2018)

Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc387bef958a19b92fb8bdb938cb0c28

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.